MDGEF (Medigene AG) Debt-to-Asset : 0.09 (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Debt-to-Asset?

Medigene AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.01 Mil. Medigene AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.73 Mil. Medigene AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $31.01 Mil. Medigene AG's debt to asset for the quarter that ended in Jun. 2024 was 0.09.

Medigene AG Debt-to-Asset Historical Data

The historical data trend for Medigene AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Debt-to-Asset Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.06

0.07

0.09

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.05	0.07	0.08	0.09	0.09

Competitive Comparison of Medigene AG's Debt-to-Asset

For the Biotechnology subindustry, Medigene AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Medigene AG's Debt-to-Asset falls into.

Medigene AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Medigene AG's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.997	+	2.22)	/	34.587
	=	0.09

Medigene AG's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.006	+	1.733)	/	31.012
	=	0.09

Medigene AG (OTCPK:MDGEF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Medigene AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Medigene AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

0QGJ:UK MDG1:Germany

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.